+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 8Years - 85Years
All Genders
ID07020819

Open-Label Study Evaluating Tanruprubart ANX005 for Guillain-Barre Syndrome Pharmacokinetics, Safety, and Early Efficacy

Led by Annexon, Inc. · Updated on 2026-10-26

30

Participants Needed

30

Research Sites

56 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating tanruprubart, also known as ANX005, in people aged 8 to 85 years with Guillain-Barre Syndrome GBS. This phase 3 open-label study aims to understand how tanruprubart behaves in the body, its effects on the immune system, early signs of its impact on GBS, and its safety profile across adult and pediatric participants in the United States, Canada, and Europe. Participants will receive a single intravenous infusion of tanruprubart at a dose of 30 mg per kilogram on the first day of the study. This single-dose treatment is designed to assess the pharmacokinetics and pharmacodynamics of the drug, along with early efficacy signals and safety data during the initial 15 days following infusion. During the study, participants will be monitored through blood tests measuring tanruprubart concentration and complement protein levels, as well as clinical assessments such as the Medical Research Council Sumscore to evaluate muscle strength changes. Researchers will focus on drug concentration over time and the time to reach maximum serum concentration. The primary measurement period extends up to day 15, with safety and efficacy monitored closely throughout this timeframe.

CONDITIONS

Brief Title

An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)

Research Team

S

Study Coordinator

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here